<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34294935</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>28</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>28</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1591-951X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>113</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Pathologica</Title>
          <ISOAbbreviation>Pathologica</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis.</ArticleTitle>
        <Pagination>
          <StartPage>170</StartPage>
          <EndPage>184</EndPage>
          <MedlinePgn>170-184</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.32074/1591-951X-245</ELocationID>
        <Abstract>
          <AbstractText>Autoimmune cholestatic liver diseases are rare hepato-biliary disorders characterized by a progressive, inflammatory destruction of bile ducts. Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are the main autoimmune cholestatic liver diseases. Both may evolve into secondary biliary cirrhosis and its complications. Therapeutic options are limited and liver transplantation remains the only definitive treatment for PBC and PSC. Most PBC and PSC patients have a typical presentation, which does not require liver biopsy. However, in routine clinical practice, important variants or specific subgroups that benefit from liver biopsy for proper management may be observed. Herein, we provide a general overview of clinical and pathological characteristic of PBC and PSC, highlighting the most important features for routine diagnostic practice.</AbstractText>
          <CopyrightInformation>Copyright © 2021 Società Italiana di Anatomia Patologica e Citopatologia Diagnostica, Divisione Italiana della International Academy of Pathology.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Sarcognato</LastName>
            <ForeName>Samantha</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Azienda ULSS2 Marca Trevigiana, Treviso, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sacchi</LastName>
            <ForeName>Diana</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Azienda ULSS2 Marca Trevigiana, Treviso, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Grillo</LastName>
            <ForeName>Federica</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Anatomic Pathology Unit, University of Genova and Policlinico San Martino Hospital, Genova, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cazzagon</LastName>
            <ForeName>Nora</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Oncology and Gastroenterology - DISCOG, University of Padova, Padova, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fabris</LastName>
            <ForeName>Luca</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Medicine - DMM, University of Padova, Padova, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cadamuro</LastName>
            <ForeName>Massimiliano</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Medicine - DMM, University of Padova, Padova, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cataldo</LastName>
            <ForeName>Ivana</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Azienda ULSS2 Marca Trevigiana, Treviso, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Covelli</LastName>
            <ForeName>Claudia</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Pathology Unit, Fondazione IRCCS "Casa Sollievo della Sofferenza", San Giovanni Rotondo, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mangia</LastName>
            <ForeName>Alessandra</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Liver Unit, Fondazione IRCCS "Casa Sollievo della Sofferenza", San Giovanni Rotondo, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guido</LastName>
            <ForeName>Maria</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Azienda ULSS2 Marca Trevigiana, Treviso, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medicine - DIMED, University of Padova, Padova, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Pathologica</MedlineTA>
        <NlmUniqueID>0401123</NlmUniqueID>
        <ISSNLinking>0031-2983</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001327" MajorTopicYN="Y">Autoimmune Diseases</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015209" MajorTopicYN="Y">Cholangitis, Sclerosing</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008105" MajorTopicYN="Y">Liver Cirrhosis, Biliary</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">PBC</Keyword>
        <Keyword MajorTopicYN="N">PSC</Keyword>
        <Keyword MajorTopicYN="N">autoimmune cholangitis</Keyword>
        <Keyword MajorTopicYN="N">immune-mediated cholangitis</Keyword>
        <Keyword MajorTopicYN="N">overlap variants</Keyword>
      </KeywordList>
      <CoiStatement><b>Conflict of interest</b>. The Authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>42</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34294935</ArticleId>
        <ArticleId IdType="pmc">PMC8299325</ArticleId>
        <ArticleId IdType="doi">10.32074/1591-951X-245</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Lazaridis KN, LaRusso NF. The cholangiopathies. Mayo Clin Proc
2015;90:791-800. https://doi.org/10.1016/j.mayocp.2015.03.017
10.1016/j.mayocp.2015.03.017</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mayocp.2015.03.017</ArticleId>
            <ArticleId IdType="pmc">PMC4533104</ArticleId>
            <ArticleId IdType="pubmed">25957621</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lazaridis KN, Strazzabosco M, Larusso NF. The cholangiopathies: disorders of biliary epithelia. Gastroenterology
2004;127:1565-1577. https://doi.org/10.1053/j.gastro.2004.08.006
10.1053/j.gastro.2004.08.006</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2004.08.006</ArticleId>
            <ArticleId IdType="pubmed">15521023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalekos GN, Gatselis NK. Variant and specific forms of autoimmune cholestatic liver diseases. Arch Immunol Ther Exp (Warsz)
2019;67:197-211. https://doi.org/10.1007/s00005-019-00550-9
10.1007/s00005-019-00550-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00005-019-00550-9</ArticleId>
            <ArticleId IdType="pubmed">31165900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harada K, Sato Y, Itatsu K, et al. . Innate immune response to double-stranded RNA in biliary epithelial cells is associated with the pathogenesis of biliary atresia. Hepatology
2007;46:1146-1154. https://doi.org/10.1002/hep.21797
10.1002/hep.21797</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.21797</ArticleId>
            <ArticleId IdType="pubmed">17661372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakanuma Y, Zen Y. Pathology and immunopathology of immunoglobulin G4-related sclerosing cholangitis: the latest addition to the sclerosing cholangitis family. Hepatol Res
2007;37:S478-486. https://doi.org/10.1111/j.1872-034X.2007.00243.x
10.1111/j.1872-034X.2007.00243.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1872-034X.2007.00243.x</ArticleId>
            <ArticleId IdType="pubmed">17931207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zen Y, Hübscher SG, Nakanuma Y. Bile duct diseases. Burt AD, Ferrell LD, Hübscher SG, eds. MacSween’s pathology of the liver. 7th ed. Philadelphia, PA: Elsevier; 
2018, p. 515.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhang W, Sharma R, Ju ST, et al. . Deficiency in regulatory T cells results in development of antimitochondrial antibodies and autoimmune cholangitis. Hepatology
2009;49:545-552. https://doi.org/10.1002/hep.22651
10.1002/hep.22651</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.22651</ArticleId>
            <ArticleId IdType="pmc">PMC2635418</ArticleId>
            <ArticleId IdType="pubmed">19065675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sasaki M, Ikeda H, Sawada S, et al. . Naturally-occurring regulatory T cells are increased in inflamed portal tracts with cholangiopathy in primary biliary cirrhosis. J Clin Pathol
2007;60:1102-1107. https://doi.org/10.1136/jcp.2006.044776
10.1136/jcp.2006.044776</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jcp.2006.044776</ArticleId>
            <ArticleId IdType="pmc">PMC2014857</ArticleId>
            <ArticleId IdType="pubmed">17158635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>European Association for the Study of the Liver. EASL Clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol
2017;67:145-172. https://doi.org/10.1016/j.jhep.2017.03.022
10.1016/j.jhep.2017.03.022</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhep.2017.03.022</ArticleId>
            <ArticleId IdType="pubmed">28427765</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carey EJ, Ali AH, Lindor KD. Primary biliary cirrhosis. Lancet
2015;386:1565-1575. https://doi.org/10.1016/S0140-6736(15)00154-3
10.1016/S0140-6736(15)00154-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(15)00154-3</ArticleId>
            <ArticleId IdType="pubmed">26364546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chalifoux SL, Konyn PG, Saab S, et al. . Extrahepatic manifestations of primary biliary cholangitis. Gut Liver
2017:11;771-780. https://doi.org/10.5009/gnl16365
10.5009/gnl16365</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5009/gnl16365</ArticleId>
            <ArticleId IdType="pmc">PMC5669592</ArticleId>
            <ArticleId IdType="pubmed">28292174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Floreani A, Cazzagon N. PBC and related extrahepatic diseases. Best Pract Res Clin Gastroenterol
2018;34-35:49-54. https://doi.org/10.1016/j.bpg.2018.05.013
10.1016/j.bpg.2018.05.013</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bpg.2018.05.013</ArticleId>
            <ArticleId IdType="pubmed">30343710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harms MH, van Buuren HR, van der Meer AJ, et al. . Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. J Hepatol
2019;71:357-365. https://doi.org/10.1016/j.jhep.2019.04.001
10.1016/j.jhep.2019.04.001</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhep.2019.04.001</ArticleId>
            <ArticleId IdType="pubmed">30980847</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirschfield GM, Dyson JK, Jones DEJ, et al. . The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. Gut
2018;67:1568-1594. https://doi.org/10.1136/gutjnl-2017-315259
10.1136/gutjnl-2017-315259</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2017-315259</ArticleId>
            <ArticleId IdType="pmc">PMC6109281</ArticleId>
            <ArticleId IdType="pubmed">29593060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Floreani A, Mangini C. Primary biliary cholangitis: old and novel therapy. Eur J Intern Med
2018;47:1-5. https://doi.org/10.1016/j.ejim.2017.06.020
10.1016/j.ejim.2017.06.020</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejim.2017.06.020</ArticleId>
            <ArticleId IdType="pubmed">28669591</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao L, Wang L, Gershwin ME, et al. . Clinical management of primary biliary cholangitis - Strategies and evolving trends. Clin Rev Allergy Immunol
2020;59:175-194. https://doi.org/10.1007/s12016-019-08772-7
10.1007/s12016-019-08772-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12016-019-08772-7</ArticleId>
            <ArticleId IdType="pubmed">31713023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lammers WJ, Hirschfield GM, Corpechot C, et al. on behalf of the Global PBC Study Group . Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy. Gastroenterology
2015;149:1804-1812.e4. https://doi.org/10.1053/j.gastro.2015.07.061
10.1053/j.gastro.2015.07.061</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2015.07.061</ArticleId>
            <ArticleId IdType="pubmed">26261009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carbone M, Sharp SJ, Flack S, et al. on behalf of the UK-PBC Consortium . The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis. Hepatology
2016;63:930-950. https://doi.org/10.1002/hep.28017
10.1002/hep.28017</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.28017</ArticleId>
            <ArticleId IdType="pmc">PMC6984963</ArticleId>
            <ArticleId IdType="pubmed">26223498</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alvaro D, Carpino G, Invernizzi P, et al. . Primary biliary cholangitis management: controversies, perspectives and daily practice implications from an expert panel. Liver Int
2020;40:2590-2601. https://doi.org/10.1111/liv.14627
10.1111/liv.14627</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/liv.14627</ArticleId>
            <ArticleId IdType="pubmed">32757367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsuneyama K, Baba H, Ogawa H, et al. . Primary biliary cholangitis: its pathological characteristics and immunopathological mechanisms. J Med Invest
2017;64:7-13. https://doi.org/10.2152/jmi.64.7
10.2152/jmi.64.7</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2152/jmi.64.7</ArticleId>
            <ArticleId IdType="pubmed">28373632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Terziroli Beretta-Piccoli B, Mieli-Vergani G, Gershwin ME, et al. . The challenges of primary biliary cholangitis: What is new and what needs to be done. J Autoimmun
2019;105:102328. https://doi.org/10.1016/j.jaut.2019.102328
10.1016/j.jaut.2019.102328</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaut.2019.102328</ArticleId>
            <ArticleId IdType="pubmed">31548157</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yokoda RT, Rodriguez EA. Review: Pathogenesis of cholestatic liver diseases. World J Hepatol
2020;12:423-435. https://doi.org/10.4254/wjh.v12.i8.423
10.4254/wjh.v12.i8.423</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4254/wjh.v12.i8.423</ArticleId>
            <ArticleId IdType="pmc">PMC7475774</ArticleId>
            <ArticleId IdType="pubmed">32952871</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan C, Koda S, Wu J, et al. . Roles of trained immunity in the pathogenesis of cholangiopathies: a therapeutic target. Hepatology
2020;72:1838-1850. https://doi.org/10.1002/hep.31395
10.1002/hep.31395</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.31395</ArticleId>
            <ArticleId IdType="pubmed">32463941</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Banales JM, Huebert RC, Gores GJ, et al. . Cholangiocyte pathobiology. Nat Rev Gastroenterol Hepatol
2019;16:269-281. doi:10.1038/s41575-019-0125-y
10.1038/s41575-019-0125-y</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41575-019-0125-y</ArticleId>
            <ArticleId IdType="pmc">PMC6563606</ArticleId>
            <ArticleId IdType="pubmed">30850822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ronca V, Mancuso C, Invernizzi P, et al. . Immune system and cholangiocytes: a puzzling affair in primary biliary cholangitis. J Leukoc Biol
2020;108:659-671. https://doi.org/10.1002/JLB.5MR0320-200R
10.1002/JLB.5MR0320-200R</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/JLB.5MR0320-200R</ArticleId>
            <ArticleId IdType="pubmed">32349179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rubin E, Schaffner F, Popper H. Primary biliary cirrhosis: chronic non-suppurative destructive cholangitis. Am J Pathol
1965;46:387-407.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1920366</ArticleId>
            <ArticleId IdType="pubmed">14266218</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakanuma Y, Harada K. Florid duct lesion in primary biliary cirrhosis shows highly proliferative activities. J Hepatol
1993;19:216-221. https://doi.org/10.1016/s0168-8278(05)80574-4
10.1016/s0168-8278(05)80574-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0168-8278(05)80574-4</ArticleId>
            <ArticleId IdType="pubmed">7905494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carpino G, Cardinale V, Gaudio E, et al. . Hepatic stem/progenitor cell activation differs between primary sclerosing and primary biliary cholangitis. Am J Pathol
2018;188:627-639. https://doi.org/10.1016/j.ajpath.2017.11.010
10.1016/j.ajpath.2017.11.010</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ajpath.2017.11.010</ArticleId>
            <ArticleId IdType="pubmed">29248458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takahashi T, Miura T, Nakamura J, et al. . Plasma cells and the chronic nonsuppurative destructive cholangitis of primary biliary cirrhosis. Hepatology
2012; 55:846-855. https://doi.org/10.1002/hep.24757
10.1002/hep.24757</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.24757</ArticleId>
            <ArticleId IdType="pmc">PMC3272098</ArticleId>
            <ArticleId IdType="pubmed">22031474</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakanuma Y, Hoso M, Mizuno Y, et al. . Pathologic study of primary biliary cirrhosis of early histologic stages presenting cholestatic jaundice. Liver
1988;8:319-324. https://doi.org/10.1111/j.1600-0676.1988.tb01010.x
10.1111/j.1600-0676.1988.tb01010.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1600-0676.1988.tb01010.x</ArticleId>
            <ArticleId IdType="pubmed">3216771</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Theise ND, Crawford JM, Nakanuma Y, et al. . Canal of Hering loss is an initiating step for primary biliary cholangitis (PBC): a hypothesis. Med Hypotheses
2020;140:109680. https://doi.org/10.1016/j.mehy.2020.109680
10.1016/j.mehy.2020.109680</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mehy.2020.109680</ArticleId>
            <ArticleId IdType="pubmed">32240960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khan FM, Komarla AR, Mendoza PG, et al. . Keratin 19 demonstration of canal of Hering loss in primary biliary cirrhosis: “minimal change PBC”?
Hepatology
2013;57:700-707. https://doi.org/10.1002/hep.26020
10.1002/hep.26020</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.26020</ArticleId>
            <ArticleId IdType="pubmed">22911653</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kakuda Y, Harada K, Nakanuma Y. Canals of Hering loss relates to the progression of the histological stages of primary biliary cirrhosis. J Clin Pathol
2015;68:141-147. https://doi.org/10.1136/jclinpath-2014-202417
10.1136/jclinpath-2014-202417</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jclinpath-2014-202417</ArticleId>
            <ArticleId IdType="pubmed">25430494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Colina F, Pinedo F, Nevado M, et al. . Nodular regenerative hyperplasia of the liver in early histological stages of primary biliary cirrhosis. Gastroenterology
1992;102:1319-1324.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1551537</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakanuma Y, Hirata K. Unusual hepatocellular lesions in primary biliary cirrhosis resembling but unrelated to hepatocellular neoplasms. Virchows Arch A Pathol Anat Histopathol
1993;422:17-23. https://doi.org/10.1007/BF01605128
10.1007/BF01605128</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF01605128</ArticleId>
            <ArticleId IdType="pubmed">8382391</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ludwig J, Dickson ER, McDonald GS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol
1978;379:103-112. https://doi.org/10.1007/BF00432479
10.1007/BF00432479</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF00432479</ArticleId>
            <ArticleId IdType="pubmed">150690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scheuer P. Primary biliary cirrhosis. Proc R Soc Med
1967;60:1257-1260</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1901478</ArticleId>
            <ArticleId IdType="pubmed">6066569</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harada K, Hsu M, Nakanuma Y, et al. . Application and validation of a new histologic staging and grading system for primary biliary cirrhosis. J Clin Gastroenterol
2013;47:174-181. https://doi.org/10.1097/MCG.0b013e31827234e4
10.1097/MCG.0b013e31827234e4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MCG.0b013e31827234e4</ArticleId>
            <ArticleId IdType="pubmed">23269312</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kakuda Y, Harada K, Sawada-Kitamura S, et al. . Evaluation of a new histologic staging and grading system for primary biliary cirrhosis in comparison with classical systems. Hum Pathol
2013;44:1107-1117. https://doi.org/10.1016/j.humpath.2012.09.017
10.1016/j.humpath.2012.09.017</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.humpath.2012.09.017</ArticleId>
            <ArticleId IdType="pubmed">23313306</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Czaja AJ, Carpenter HA. Autoimmune hepatitis with incidental histologic features of bile duct injury. Hepatology
2001;34:659-665. https://doi.org/10.1053/jhep.2001.27562
10.1053/jhep.2001.27562</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/jhep.2001.27562</ArticleId>
            <ArticleId IdType="pubmed">11584360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verdonk RC, Lozano MF, Gouw ASH, et al. . Bile ductal injury and ductular reaction are frequent phenomena with different significance in autoimmune hepatitis. Liver Int
2016;36:1362-1369. https://doi.org/10.1111/liv.13083
10.1111/liv.13083</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/liv.13083</ArticleId>
            <ArticleId IdType="pubmed">26849025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Balitzer D, Shafizadeh N, Kakar S, et al. . Autoimmune hepatitis: review of histologic features included in the simplified criteria proposed by the international autoimmune hepatitis group and proposal for new histologic criteria. Mod Pathol
2017;30:773-783. https://doi.org/10.1038/modpathol.2016.267
10.1038/modpathol.2016.267</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/modpathol.2016.267</ArticleId>
            <ArticleId IdType="pubmed">28106105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goet JC, Harms MH, Hansen BE, et al. . Risk stratification and prognostic modelling in primary biliary cholangitis. Best Pract Res Clin Gastroenterol
2018;34-35:95-106. https://doi.org/10.1016/j.bpg.2018.06.006
10.1016/j.bpg.2018.06.006</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bpg.2018.06.006</ArticleId>
            <ArticleId IdType="pubmed">30343715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kobayashi M, Kakuda Y, Harada K, et al. . Clinicopathological study of primary biliary cirrhosis with interface hepatitis compared to autoimmune hepatitis. World J Gastroenterol
2014;20:3597-3608. https://doi.org/10.3748/wjg.v20.i13.3597
10.3748/wjg.v20.i13.3597</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3748/wjg.v20.i13.3597</ArticleId>
            <ArticleId IdType="pmc">PMC3974527</ArticleId>
            <ArticleId IdType="pubmed">24707143</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tan D, Goodman ZD. Liver biopsy in primary biliary cholangitis: indications and interpretation. Clin Liver Dis
2018;22:579-588. https://doi.org/10.1016/j.cld.2018.03.008
10.1016/j.cld.2018.03.008</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cld.2018.03.008</ArticleId>
            <ArticleId IdType="pubmed">30259854</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karlsen TH, Folseraas T, Vesterhus M, et al. . Primary sclerosing cholangitis - a comprehensive review. J Hepatol
2017;67:1298-1323. https://doi.org/10.1016/j.jhep.2017.07.022
10.1016/j.jhep.2017.07.022</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhep.2017.07.022</ArticleId>
            <ArticleId IdType="pubmed">28802875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirschfield GM, Karlsen TH, Adams DH, et al. . Primary sclerosing cholangitis. Lancet
2013;382:1587-1599. https://doi.org/10.1016/S0140-6736(13)60096-3
10.1016/S0140-6736(13)60096-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(13)60096-3</ArticleId>
            <ArticleId IdType="pubmed">23810223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lazaridis KN, LaRusso NF. Primary sclerosing cholangitis. N Engl J Med
2016;375:1161-1170. https://doi.org/10.1056/NEJMra1506330
10.1056/NEJMra1506330</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMra1506330</ArticleId>
            <ArticleId IdType="pmc">PMC5553912</ArticleId>
            <ArticleId IdType="pubmed">27653566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Angulo P, Peter JB, Gershwin ME, et al. . Serum autoantibodies in patients with primary sclerosing cholangitis. J Hepatol
2000;32:182-187. https://doi.org/10.1016/s0168-8278(00)80061-6
10.1016/s0168-8278(00)80061-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0168-8278(00)80061-6</ArticleId>
            <ArticleId IdType="pubmed">10707856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lindor KD, Kowdley KV, Harrison ME. ACG Clinical guideline: primary sclerosing cholangitis. Am J Gastroenterol
2015;110:646-659. https://doi.org/10.1038/ajg.2015.112
10.1038/ajg.2015.112</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ajg.2015.112</ArticleId>
            <ArticleId IdType="pubmed">25869391</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chapman MH, Thorburn D, Hirschfield GM, et al. . British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis. Gut
2019;68:1356-1378. https://doi.org/10.1136/gutjnl-2018-317993
10.1136/gutjnl-2018-317993</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2018-317993</ArticleId>
            <ArticleId IdType="pmc">PMC6691863</ArticleId>
            <ArticleId IdType="pubmed">31154395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aabakken L, Karlsen TH, Hassan C, et al. . Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) clinical guideline. Endoscopy
2017;49:588-608. https://doi.org/10.1055/s-0043-107029
10.1055/s-0043-107029</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-0043-107029</ArticleId>
            <ArticleId IdType="pubmed">28420030</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim WR, Therneau TM, Dickson ER, et al. . A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc
2000;75:688-694. https://doi.org/10.4065/75.7.688
10.4065/75.7.688</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4065/75.7.688</ArticleId>
            <ArticleId IdType="pubmed">10907383</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Vries EM, Wang J, Ponsioen CY, et al. . A novel prognostic model for transplant-free survival in primary sclerosing cholangitis. Gut
2018;67:1864-1869. https://doi.org/10.1136/gutjnl-2016-313681
10.1136/gutjnl-2016-313681</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2016-313681</ArticleId>
            <ArticleId IdType="pmc">PMC6145288</ArticleId>
            <ArticleId IdType="pubmed">28739581</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iravani S, Dooghaie-Moghadam A, Razavi-Khorasani N, et al. . An update on treatment options for primary sclerosing cholangitis. Gastroenterol Hepatol Bed Bench
2020;13:115-124.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7149806</ArticleId>
            <ArticleId IdType="pubmed">32308932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dean G, Hanauer S, Levitsky J. The role of the intestine in the pathogenesis of primary sclerosing cholangitis: evidence and therapeutic implications. Hepatology
2020;72:1127-1138. https://doi.org/10.1002/hep.31311
10.1002/hep.31311</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.31311</ArticleId>
            <ArticleId IdType="pubmed">32394535</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shah A, Macdonald GA, Morrison M, et al. . Targeting the gut microbiome as a treatment for primary sclerosing cholangitis: a conceptional framework. Am J Gastroenterol
2020;115:814-822. https://doi.org/10.14309/ajg.0000000000000604
10.14309/ajg.0000000000000604</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.14309/ajg.0000000000000604</ArticleId>
            <ArticleId IdType="pmc">PMC7269024</ArticleId>
            <ArticleId IdType="pubmed">32250997</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Portmann B, Zen Y. Inflammatory disease of the bile ducts-cholangiopathies: liver biopsy challenge and clinicopathological correlation. Histopathology
2012;60:236-248. https://doi.org/10.1111/j.1365-2559.2011.03853.x
10.1111/j.1365-2559.2011.03853.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2559.2011.03853.x</ArticleId>
            <ArticleId IdType="pubmed">21668470</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Colling R, Verrill C, Fleming K, et al. . Bile duct basement membrane thickening in primary sclerosing cholangitis. Histopathology
2016;68:819-824. https://doi.org/10.1111/his.12857
10.1111/his.12857</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/his.12857</ArticleId>
            <ArticleId IdType="pubmed">26333410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fiel MI, Sima HR, Schiano TD, et al. . A morphometric study of the hepatic arterioles in end-stage primary sclerosing cholangitis. Virchows Arch
2015;466:143-149. https://doi.org/10.1007/s00428-014-1680-9
10.1007/s00428-014-1680-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00428-014-1680-9</ArticleId>
            <ArticleId IdType="pubmed">25416080</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carrasco-Avino G, Thomas D, Schiano TD, Fiel MI, et al. . Primary sclerosing cholangitis: detailed histologic assessment and integration using bioinformatics highlights arterial fibrointimal hyperplasia as a novel feature. Am J Clin Pathol
2015;143:505-513. https://doi.org/10.1309/AJCPVKFVIPRBXQR2
10.1309/AJCPVKFVIPRBXQR2</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1309/AJCPVKFVIPRBXQR2</ArticleId>
            <ArticleId IdType="pubmed">25780002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Vries EM, de Krijger M, Ponsioen CY, et al. . Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: an international cohort study. Hepatology
2017;65:907-919. https://doi.org/10.1002/hep.28963
10.1002/hep.28963</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.28963</ArticleId>
            <ArticleId IdType="pubmed">27880989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boberg KM, Chapman RW, Hirschfield GM, et al. International Autoimmune Hepatitis Group . Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol
2011;54:374-385. https://doi.org/10.1016/j.jhep.2010.09.002
10.1016/j.jhep.2010.09.002</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhep.2010.09.002</ArticleId>
            <ArticleId IdType="pubmed">21067838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuiper EMM, Zondervan PE, van Buuren HR. Paris criteria are effective in diagnosis of primary biliary cirrhosis and autoimmune hepatitis overlap syndrome. Clin Gastroenterol Hepatol
2010;8:530-534. https://doi.org/10.1016/j.cgh.2010.03.004
10.1016/j.cgh.2010.03.004</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cgh.2010.03.004</ArticleId>
            <ArticleId IdType="pubmed">20304098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chazouilleres O, Wendum D, Serfaty L, et al. . Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology
1998;28:296-301. https://doi.org/10.1002/hep.510280203
10.1002/hep.510280203</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.510280203</ArticleId>
            <ArticleId IdType="pubmed">9695990</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Q, Selmi C, Zhou X, et al. . Epigenetic considerations and the clinical reevaluation of the overlap syndrome between primary biliary cirrhosis and autoimmune hepatitis. J Autoimmun
2013;41:140-145. https://doi.org/10.1016/j.jaut.2012.10.004
10.1016/j.jaut.2012.10.004</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaut.2012.10.004</ArticleId>
            <ArticleId IdType="pubmed">23187010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang W, De D, Bacon BR, et al. . New scoring classification for primary biliary cholangitis-autoimmune hepatitis overlap syndrome. Hepatol Commun
2018;2:245-253. https://doi.org/10.1002/hep4.1148
10.1002/hep4.1148</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep4.1148</ArticleId>
            <ArticleId IdType="pmc">PMC5831022</ArticleId>
            <ArticleId IdType="pubmed">29507900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalekos GN, Koskinas J, Papatheodoridis GV. Hellenic Association for the Study of the Liver (HASL) clinical practice guidelines: autoimmune hepatitis. Ann Gastroenterol
2019;32:1-23. https://doi.org/10.20524/aog.2018.0330
10.20524/aog.2018.0330</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.20524/aog.2018.0330</ArticleId>
            <ArticleId IdType="pmc">PMC6302199</ArticleId>
            <ArticleId IdType="pubmed">30598587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee H, Stapp RT, Shah VV, et al. . The usefulness of IgG and IgM immunostaining of periportal inflammatory cells (plasma cells and lymphocytes) for the distinction of autoimmune hepatitis and primary biliary cirrhosis and their staining pattern in autoimmune hepatitis-primary biliary cirrhosis overlap syndrome. Am J Clin Pathol
2010;133:430-437. https://doi.org/10.1309/AJCPE93GZSHUNTAI
10.1309/AJCPE93GZSHUNTAI</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1309/AJCPE93GZSHUNTAI</ArticleId>
            <ArticleId IdType="pubmed">20154281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abe K, Takahashi A, Nozawa Y, et al. . The utility of IgG, IgM, and CD138 immunohistochemistry in the evaluation of autoimmune liver diseases. Med Mol Morphol
2014;47:162-168. https://doi.org/10.1007/s00795-014-0082-z
10.1007/s00795-014-0082-z</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00795-014-0082-z</ArticleId>
            <ArticleId IdType="pubmed">24969678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang F, Wang O, Wang Z, et al. . The natural history and prognosis of primary biliary cirrhosis with clinical features of autoimmune hepatitis. Clin Rev Allergy Immunol
2016;50:114-123. https://doi.org/10.1007/s12016-015-8516-5
10.1007/s12016-015-8516-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12016-015-8516-5</ArticleId>
            <ArticleId IdType="pubmed">26411425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ozaslan E, Efe C, Heurgue-Berlot A, et al. . Factors associated with response to therapy and outcome of patients with primary biliary cirrhosis with features of autoimmune hepatitis. Clin Gastroenterol Hepatol
2014;12:863-869. https://doi.org/10.1016/j.cgh.2013.09.021
10.1016/j.cgh.2013.09.021</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cgh.2013.09.021</ArticleId>
            <ArticleId IdType="pubmed">24076417</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang H, Li S, Yang J, et al. . A meta-analysis of ursodeoxycholic acid therapy versus combination therapy with corticosteroids for PBC-AIH-overlap syndrome: evidence from 97 monotherapy and 117 combinations. Prz Gastroenterol
2015;10:148-155. https://doi.org/10.5114/pg.2015.51187
10.5114/pg.2015.51187</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5114/pg.2015.51187</ArticleId>
            <ArticleId IdType="pmc">PMC4607695</ArticleId>
            <ArticleId IdType="pubmed">26516380</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deneau MR, El-Matary W, Valentino PL, et al. . The natural history of primary sclerosing cholangitis in 781 children: a multicenter, international collaboration. Hepatology
2017;66:518-527. https://doi.org/10.1002/hep.29204
10.1002/hep.29204</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.29204</ArticleId>
            <ArticleId IdType="pubmed">28390159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weismüller TJ, Trivedi PJ, Bergquist A, et al. International PSC Study Group . Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis. Gastroenterology
2017;152:1975-1984.e8. https://doi.org/10.1053/j.gastro.2017.02.038
10.1053/j.gastro.2017.02.038</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2017.02.038</ArticleId>
            <ArticleId IdType="pmc">PMC5546611</ArticleId>
            <ArticleId IdType="pubmed">28274849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Olsson R, Glaumann H, Almer S, et al. . High prevalence of small duct primary sclerosing cholangitis among patients with overlapping autoimmune hepatitis and primary sclerosing cholangitis. Eur J Intern Med
2009;20:190-196. https://doi.org/10.1016/j.ejim.2008.06.004
10.1016/j.ejim.2008.06.004</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejim.2008.06.004</ArticleId>
            <ArticleId IdType="pubmed">19327611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gregorio GV, Portmann B, Karani J, et al. . Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology
2001;33:544-553. https://doi.org/10.1053/jhep.2001.22131
10.1053/jhep.2001.22131</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/jhep.2001.22131</ArticleId>
            <ArticleId IdType="pubmed">11230733</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rojas CP, Bodicharla R, Campuzano-Zuluanga G, et al. . Autoimmune hepatitis and primary sclerosing cholangitis in children and adolescents. Fetal Pediatr Pathol
2014;33:202-209. https://doi.org/10.3109/15513815.2014.898721
10.3109/15513815.2014.898721</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/15513815.2014.898721</ArticleId>
            <ArticleId IdType="pmc">PMC4086229</ArticleId>
            <ArticleId IdType="pubmed">24754367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oliveira EMG, Oliveira PM, Becker V, et al. . Overlapping of primary biliary cirrhosis and small duct primary sclerosing cholangitis: first case report. J Clin Med Res
2012;4:429-433. https://doi.org/10.4021/jocmr1060w
10.4021/jocmr1060w</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4021/jocmr1060w</ArticleId>
            <ArticleId IdType="pmc">PMC3513426</ArticleId>
            <ArticleId IdType="pubmed">23226177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Floreani A, Motta R, Cazzagon N, et al. . The overlap syndrome between primary biliary cirrhosis and primary sclerosing cholangitis. Dig Liver Dis
2015;47:432-435. https://doi.org/10.1016/j.dld.2015.02.002
10.1016/j.dld.2015.02.002</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.dld.2015.02.002</ArticleId>
            <ArticleId IdType="pubmed">25747115</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sundaram S, K S, Mazumdar S, et al. . Overlap syndrome between primary biliary cholangitis and primary sclerosing cholangitis. ACG Case Rep J
2018;5:e54. https://doi.org/10.14309/crj.2018.54
10.14309/crj.2018.54</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.14309/crj.2018.54</ArticleId>
            <ArticleId IdType="pmc">PMC6053546</ArticleId>
            <ArticleId IdType="pubmed">30038926</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
